Clinical trials: Absorption; Disorder
Neurogenic Detrusor Overactivity, Overactive Bladder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
- Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
- Trial name
- NCT02211846
- Testing
- Mirabegron
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
Healthy
A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases
The purpose of this study is to investigate how safe 2 different formulations (immediate-release (IR) and modified-release (MR) tablets) of the new compound GLPG3312 are and how well they are tolerated when they are administered…
- Trial name
- NCT03800472
- Testing
- GLPG3312 IR, GLPG3312 MR, GLPG3312 FE MR
- Where
- Netherlands
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Type 2 Diabetes Mellitus, Weight Loss
Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects
This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of [14C]HRS9531.
- Trial name
- NCT06855147
- Testing
- [14C]HRS9531
- Where
- China
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Primary Hypercholesterolemia
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with primary hypercholesterolemia.
- Trial name
- NCT02087917
- Testing
- HS-25
- Where
- 27 sites in United States
- Volunteers
- 376 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Lupus Erythematosus, Systemic
Evaluation of the Influence of Food Regimen on Oshadi D Absorption
The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects.
- Trial name
- NCT01327352
- Testing
- Oshadi D
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oshadi Drug Administration
Migraine Disorders
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
- Trial name
- NCT00385008
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food
This study in RLS patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat…
- Trial name
- NCT00419692
- Testing
- Ropinirole
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Absorption & Elimination of Radiolabelled GSK2269557
GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
- Trial name
- NCT03315559
- Testing
- [14C]-GSK2269557 IV infusion, GSK2269557 via DPI, [14C]-GSK2269557 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Insufficiency, Chronic
To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
The study investigates the pharmacokinetics (absorption, distribution, elimination) of molidustat after intake of a single 75 mg tablet in subjects with renal impairment requiring hemo- or peritoneal dialysis compared to age-and…
- Trial name
- NCT02312973
- Testing
- Molidustat(BAY85-3934)
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Chronic Myeloid Leukemia (CML)
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 30mg (100µCi) dose of [14C] HQP1351 given as a suspension.
- Trial name
- NCT04126707
- Testing
- [14C] HQP1351
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Ascentage Pharma Group Inc.
Healthy Volunteers, Cardiometabolic Diseases
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems.
- Trial name
- NCT07797855
- Testing
- NNC0705-0002
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type II Diabetes Mellitus
Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)
The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.
- Trial name
- ADME (NCT00960791)
- Testing
- AZD1656
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Fabry Disease
A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
This study is designed to describe the metabolism of AT1001 (migalastat HCl) and the contribution of metabolism and urinary excretion to its overall elimination as part of the continuing assessment of the safety and effectiveness…
- Trial name
- NCT01730482
- Testing
- [14C] AT1001
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Type 2 Diabetes Mellitus (T2DM)
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
- Trial name
- NCT01127308
- Testing
- Ertugliflozin
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02772159
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Psoriasis
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
The primary objective of this study will be to evaluate the efficacy of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects.
- Trial name
- NCT00782613
- Testing
- 4,4-dimethyl-benziso-2H-selenazine
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Synvista Therapeutics, Inc
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC